voo-- the problem is that the stock can never gain momentum when they allow it to crash into the teens before they make an announcement. They did this before the announcement that the clinical trials actually began. The announcement-though significant- only propelled the stock into the low.003s-to only pre-chill valuation. The stock is undervalued because there is no interest which doesn't help Cyrcadia to get the capital that they need to take this over the finish line. Simple supply and demand. They still haven't sold out their Series A shares as far as I know. You need a little sizzle to sell the steak.
News 
Market Data 
Discover 
AI
